HRTX - Heron Therapeutics Inc. (HRTX) Q4 2023 Earnings Call Transcript
2024-03-12 22:35:08 ET
Heron Therapeutics, Inc. (HRTX)
Q4 2023 Earnings Conference Call
March 12, 2024 4:30 PM ET
Company Participants
Craig Collard – Chief Executive Officer
Kevin Warner – Senior Vice President-Medical Affairs Strategy and Engagement
Bill Forbes – Executive Vice President and Chief Development Officer
Ira Duarte – Executive Vice President and Chief Financial Officer
Conference Call Participants
Serge Belanger – Needham & Company
Carl Byrnes – Northland Capital Markets
Presentation
Operator
Thank you for standing by, and welcome to the Heron Therapeutics Fourth Quarter 2023 Conference Call. I would now like to welcome Melissa Durel [ph], Executive Director, Legal to begin the call. Melissa, over to you.
Unidentified Company Representative
Thank you, operator, and good afternoon everyone. Thank you for joining us on the Heron Therapeutics conference call this afternoon to discuss the company's financial results for the fourth quarter ended December 31, 2023. With me today from Heron are Craig Collard, Chief Executive Officer; Ira Duarte, Executive Vice President, Chief Financial Officer; Bill Forbes, Executive Vice President, Chief Development Officer; and Kevin Warner, Senior Vice President, Medical Affairs Strategy and Engagement. For those of you participating via conference call, slides are made available via webcast and can also be accessed via the Investor Relations page of our website following the conclusion of today's call.
Before we begin, let me quickly remind you that during the course of this conference call, the company will make forward-looking statements. We caution you that any statement that is not a statement of historical fact is a forward-looking statement. This includes remarks about the company's projections, expectations, plans, beliefs and future performance, all of which constitute forward-looking statements for the purposes of the Safe Harbor provision under the Private Securities Litigation Reform Act of 1995. These statements are based on judgment and analysis as of the date of this conference call and are subject to numerous important risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties associated with the forward-looking statements made in this conference call and webcast are described in the Safe Harbor statement in today's press release and in Heron's public periodic filings with the SEC. Except as required by law, Heron assumes no obligation to update these forward-looking statements to reflect future events or actual outcomes and does not intend to do so....
Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript